BEXIMCO PHARMA.GDR REGS 1 Total Assets
BEXIMCO PHARMA.GDR REGS 1 total assets. Based on the latest financial reports, BEXIMCO PHARMA.GDR REGS 1 (R2WA) holds total assets worth €73.80 Billion EUR (≈ $86.28 Billion USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see R2WA market cap overview for the company's overall valuation and market capitalisation.
Total Assets of BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
Total assets of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024. This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's total assets have evolved over time, based on quarterly financial data. See R2WA stock price and chart for real-time trading data and today's change.
BEXIMCO PHARMA.GDR REGS 1 - Asset Composition Analysis
BEXIMCO PHARMA.GDR REGS 1 Total Assets Breakdown (June 2024)
BEXIMCO PHARMA.GDR REGS 1 total assets breakdown as of June 2024. BEXIMCO PHARMA.GDR REGS 1's total assets of €73.80 Billion consist of 30.0% current assets and 70.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.2% |
| Accounts Receivable | €3.46 Billion | 5.0% |
| Inventory | €13.01 Billion | 18.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.72 Billion | 6.8% |
| Goodwill | €674.57 Million | 1.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of BEXIMCO PHARMA.GDR REGS 1 to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BEXIMCO PHARMA.GDR REGS 1's current assets represent 30.0% of total assets in 2024, an increase from 26.4% in 2021.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, down from 1.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 3.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 18.8% of total assets.
BEXIMCO PHARMA.GDR REGS 1 Competitors by Total Assets
Key competitors of BEXIMCO PHARMA.GDR REGS 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
BEXIMCO PHARMA.GDR REGS 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 2.18 | 2.18 |
| Quick Ratio | 0.83 | 0.82 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €13.09 Billion | €11.26 Billion | €11.26 Billion |
BEXIMCO PHARMA.GDR REGS 1 - Advanced Valuation Insights
This section examines the relationship between BEXIMCO PHARMA.GDR REGS 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.32 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | €69.34 Billion |
| Market Capitalization | $208.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values BEXIMCO PHARMA.GDR REGS 1's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: BEXIMCO PHARMA.GDR REGS 1's assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below shows the annual total assets of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €69.34 Billion ≈ $81.07 Billion |
+0.27% |
| 2023-06-30 | €69.16 Billion ≈ $80.85 Billion |
+4.55% |
| 2022-06-30 | €66.15 Billion ≈ $77.33 Billion |
+26.61% |
| 2021-06-30 | €52.25 Billion ≈ $61.08 Billion |
-- |
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more